Evaluation of the immunomodulatory effects of therapy with Brentuximab (IMMBRE)

Study identification

• EU PAS number:
  EUPAS13579
• Study ID:
  13580
• Official title and acronym:
  Evaluation of the immunomodulatory effects of therapy with Brentuximab (IMMBRE)
• DARWIN EU® study:
  No
• Study countries:
  Italy
• Study description:
  Evaluation of CD30 as a marker of immunosuppressive cells by analysis of the potential immunomodulatory effect of treatment with Brentuximab in patients with lymphoma
• Study status:
  Finalised

Research institutions and networks

Institutions

Fondazione IRCCS Istituto Nazionale dei Tumori

Study timelines

Date when funding contract was signed

Planned: 18/05/2016

Actual: 25/05/2016

Study start date

Planned: 19/05/2016

Actual: 25/05/2016

Date of final study report

Planned: 31/05/2019

Actual: 25/05/2016

Sources of funding

Pharmaceutical company and other private sector 

Non-for-profit organisation (e.g. charity)

EU institutional research programme

Other

More details on funding

Name of pharmaceutical company(ies), Charities, Government body, Research councils, EU funding scheme not provided; Other: funding of the facility

Regulatory

• Was the study required by a regulatory body?:
  No